Drugs for disorders of the senses (A61P27)

A   Human necessities(312083)
A61P27                 Drugs for disorders of the senses(948)
A61P27/02 - Ophthalmic agents(575)
A61P27/08 - ydriatics or cycloplegics(6)
A61P27/12 - For cataracts(30)
A61P27/16 - Otologicals(67)

Fluorine-9-methyl-β-carbolines // 2642785
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of the general formula (I) , where R1 is -F, and R2 is -H or -F, or R1 is -H, and R2 is -F; which can be used as a medicine for treatment of diseases and/or injuries of the inner ear.EFFECT: increased efficiency of compounds.10 cl, 30 dwg, 1 tbl, 9 ex

Compositions and methods for inhibition of cellular adhesion or direction of diagnostic or therapeutic agents to rgd binding sites // 2642625
FIELD: pharmacology.SUBSTANCE: group of inventions concerns a peptide containing the glycine-arginine-glycine-cysteic acid-threonine-proline sequence, which inhibits cell adhesion to RGD binding sites. A composition, and a method for vitreoretinal disease treatment, and a method for stimulation of vitreolysis, dilation of the vitreous or vitreoretinal detachment are also described.EFFECT: group of inventions provides treatment of retinal diseases or simplified removal of the vitreous body during vitrectomy.10 cl, 6 ex, 5 dwg, 2 tbl

Composition and method for treatment of eye disease assiciated with nucleic acids // 2642609
FIELD: medicine.SUBSTANCE: composition for treatment of dry eyes syndrome associated with nucleic acids, which develops as a result of nucleic acids formation/generation together with formation of eye mucoid films and/or biofilms, contains deoxyribonuclease I (DNAase I) and ophthalmologic auxiliary substance, and does not contain antibiotics. The composition is applied to the eye surface to remove the nucleic acid from the eye surface. Also, a method for treatment of the said dry eyes syndrome is provided, comprising administration of the said composition to the eye in an effective amount.EFFECT: application of the group of inventions improves treatment of the dry eyes syndrome associated with nucleic acids, which develops as a result of formation, generation of nucleic acids together with formation of eye mucoid films or biofilms.13 cl, 16 dwg, 7 ex
Cyclosporine suspensions a of form 2 // 2641963
FIELD: pharmacology.SUBSTANCE: group of inventions represents: an ophthalmic suspension, containing cyclosporine A of form 2 and some medium, where cyclosporine A of form 2 is characterized by peaks in X-ray diffractometer scanning with the radiation of Cu Kα, 2θ: 7.5, 8.8, 10.2, 11.3, 12.7, 13.8, 14.5, 15.6 and 17.5; method of preparation of cyclosporine composition, which includes the stages of mixing cyclosporine A of form 2 with the medium for producing the suspension; suspension quassation; ophthalmic suspension, containing particles of cyclosporine A of form 2; and the medium, in which the average particle size (d90) is less than about 10 micron; method of treatment of a condition selected from: dry eye syndrome, blepharitis, tarsal glands disease, impaired awareness of corneal, allergic conjunctivitis, atopic keratoconjunctivitis, spring keratoconjunctivitis and pterygium, including the stage of applying said ophthalmic suspension to the patient, being in this condition.EFFECT: increased bioavailability, reduced foreign body sensation and achieved high stability.15 cl, 18 dwg, 2 ex, 2 tbl

Biodegradable devices based on silicon for therapeutic agents delivery // 2640918
FIELD: medicine.SUBSTANCE: biodegradable devices are described, such as implants for the controlled delivery of therapeutic agents, in particular large molecules such as proteins and antibodies. The devices contain a porous silicon carrier material impregnated with a therapeutic agent. An improved dosage form for controlled release of therapeutic agents can be used in vitro or in vivo to deliver the therapeutic agent during an estimated period of time, for example, several days, weeks or months.EFFECT: device can be used to treat or prevent the patient's conditions, such as chronic diseases.19 cl, 3 dwg, 6 tbl, 6 ex
Esters for treatment of ophthalmological inflammatory diseases // 2640506
FIELD: medicine.SUBSTANCE: invention is an ophthalmic composition for administration to a silicone hydrogel contact lens for treatment, prevention or alleviation of dry eye syndrome, wherein the composition comprises an anti-inflammatory lipoid mediator ester in an amount of about 0.01% to 5.0% by weight, calculated for the total weight of the composition, wherein the anti-inflammatory lipid mediator is ethyl alpha-linoleic acid ether and propylene glycol, wherein the anti-inflammatory lipoid mediator is present in the form of an ester.EFFECT: Improved absorption of an ester of an anti-inflammatory lipoid mediator in a silicone hydrogel contact lens.12 cl, 13 ex, 12 tbl
odulators of atp-binding cartridge transporters // 2640420
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of the formula II , where R is H, OH, OCH3, or two R taken together form -OCH2O- or -OCF2O-; R1 is H or up to two C1-C6alkyls; R2 is H or halogen; and R3 is H or C1-C6 alkyl; R3 is H or C1-C6 alkyl; Y is O or NR4; and R4 is H or C1-C6 alkyl, and their pharmaceutical compositions useful as modulators of ATP-binding cassette ("ABC") transporters, or fragments thereof, including a cystic fibrosis transmembrane conduction regulator ("CFTR"). This invention also relates to methods for treatment of diseases mediated by ABC transporters using the compounds of the invention.EFFECT: increased efficiency of treatment.19 cl, 2 tbl, 1 ex
Phenyl derivative // 2639875
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of the general formula (I) having a high antagonistic activity with respect to human S1P2, and can be used to prepare a drug for treatment of a disease mediated by S1P2, such as a disease caused by vasoconstriction, fibrosis and respiratory disease.EFFECT: compound application efficiency increase.14 cl, 2 tbl, 9 ex

Ophthalmic composition // 2639472
FIELD: pharmacology.SUBSTANCE: ophthalmic composition in the form of eye drops contains a polyaphron dispersion and has a viscosity of 1 to 50 Pa⋅S at a shear rate of 1 s-1,wherein the said composition comprises a non-ionic, non-halogenated surfactant, a pharmaceutically acceptable oil selected from the group consisting of castor oil, long chain triglycerides, medium chain triglycerides, mineral oil, silicones, phospholipids, mono- and diglycerides, and mixtures of two or more thereof, and a pharmaceutically active agent - cyclosporin, wherein the composition does not contain a fluorinated surfactant.EFFECT: improved active agent penetration through the cornea.14 cl, 10 ex, 1 dwg

Composition of prolonged action of cyclosporin of form 2 // 2639393
FIELD: pharmacology.SUBSTANCE: group of inventions is an ophthalmic composition containing cyclosporin A of form 2 and any hydrogel where cyclosporin of form 2 is characterized by peaks when scanned with X-ray diffractometer with the radiation of Cu Kα, 2θ: 7.5, 8.8, 10.2, 11.3, 12.7, 13.8, 14.5, 15.6 and 17.5; as well as a method to treat the condition selected from the following: dry eye syndrome, blepharitis, meibomian gland disease, violation of corneal sensitivity, allergic conjunctivitis, atopic keratoconjunctivitis and pterygium, including a stage of administration of said composition to the patient, who has such a condition.EFFECT: increased bioavailability, reduced foreign body sensation and achieved high stability.6 cl, 8 dwg, 3 tbl, 1 ex
ethod for treatment of olfactory dysfunction in patients with acute rhinosinusitis // 2638688
FIELD: medicine.SUBSTANCE: method includes application of local decongestants, irrigation, anti-inflammatory and mucolytic therapy. After acute manifestations of the disease subside, multichannel electrical stimulation is performed on the areas of the chewing muscles, nose wings muscles, the circular muscle of the mouth and the trapezium from both sides. Electrical stimulation is carried out by bipolar-pulse current with a trapezoidal envelope by a premise and a pause of 2 s, with a frequency of 20-120 MHz, current strength to low vibration of muscles under the electrodes. Exposure duration is 10-15 minutes. After this, a leech is placed on the lateral wall of the nose vestibule on one side for 10-12 minutes. The course of physiotherapeutic treatment is 4-5 combined weekly procedures.EFFECT: increased effectiveness of olfactory dysfunction treatment in patients with acute rhinosinusitis due to a multifactorial sequential action on all segments of the olfactory analyzer and the autonomic nervous system.1 ex
New eye droplets for conservative treatment and prevention of the age-related nuclear cataract // 2637875
FIELD: pharmacology.SUBSTANCE: eye droplets for prevention and treatment of age-related nuclear cataract contain the following components: sodium chloride - 4.1 mg, sodium dihydrogen phosphate (monohydrate) - 4.6 mg, sodium hydrophosphate (ahydrous) - 4.74 mg, benzalkonium chloride - 0.2 mg, ondansetron hydrochloride dihydrate - 0.002-0.2 mg and water for injection - 1.0 ml.EFFECT: application of the invention provides highly effective eye droplets for the conservative treatment and prevention of age-related nuclear cataract, taking into account the pathogenetically substantiated need for a differentiated approach to treatment of different types of age-related cataract.1 tbl, 3 ex

New npr-b agonists // 2636738
FIELD: pharmacology.SUBSTANCE: invention relates to new peptides having the activity of NPR-B agonists that can be used to treat and prevent disorders mediated by natriuretic peptides, for example, such as glaucoma, eye hypertension and optical neuropathies.EFFECT: increased efficiency of treatment.21 cl, 3 dwg, 5 tbl, 5 ex

Form of 2 cyclosporin a and method of its production // 2635547
FIELD: chemistry.SUBSTANCE: method of producing Form 2 of cyclosporin A, which is a kinetically stable form of cyclosporin A in aqueous suspensions. The method of producing Form 2 of cyclosporin A, characterized by basic crystal peaks of 2θ X-ray powder diffractogram at 7.5, 8.8, 10.2, 11.3, 12.7, 13.8, 14.5, 15.6 and 17.5 includes the steps of: a) preparing a suspension of cyclosporin A in a solvent containing water and an ingredient selected from the group consisting of acetonitrile, 1,4-dioxane and ethanol; b) the first heating-cooling cycle comprising heating the slurry to a temperature of 5 to 50°C, then cooling the slurry to a temperature of 1 to 35°C; c) the second heating-cooling cycle comprising heating the slurry to a temperature of 5 to 50°C, then cooling the slurry to a temperature of 1 to 35°C and d) the third heating-cooling cycle comprising heating the slurry to a temperature of 5 to 50°C, then cooling the slurry to a temperature of 1 to 35°C.EFFECT: method improvement.14 cl, 9 dwg, 3 tbl, 1 ex
ethod for treatment of vascularized corneal leukoma resulting from eye burn injury // 2635540
FIELD: medicine.SUBSTANCE: for method implementation, a peptide preparation is placed in the conjunctival cavity: from the first to the 14th day - six times within an hour with a 10 minute interval between instillations, then from the 14th to the 30th day - four times within an hour with an interval of 20 minutes. To produce a peptide solution, a mononuclear fraction of bone marrow cells is isolated. The mononuclear cell suspension is then plated on petri dishes and cultured in DMEM medium supplemented with 10% fetal bovine serum. After obtaining of a cellular monolayer, the culture medium is completely changed and after 3 days the conditioned culture medium is combined with the lysate of mesenchymal stem cells (MSC). The cell culture is destroyed using physical and chemical methods.EFFECT: restoration of the cornea transparency, achievement of complete and persistent regression of corneal neovascularization, non-invasive treatment.1 cl

Treatment regimens and methods for visual function improvement in case of vision disorders related to endogenous retinoid deficiency // 2635536
FIELD: medicine.SUBSTANCE: first therapeutic dose of the synthetic retinal derivative is administered to a subject with a deficiency of endogenously produced 11-cis-retinal in the form of a divided daily dose over a period of about 2 to about 7 days. Next, a rest period of about 7 to about 28 days is provided. Next, the second therapeutic dose of the synthetic retinal derivative is administered to the said subject at the end of the rest period. The synthetic retinal derivative is selected from 9-cis-retinyl ester or an 11-cis-retinyl ester. The said subject has a decrease in visual function prior to administration of the second therapeutic dose. In other embodiments, methods and a set are provided to improve visual function in a subject having a mutation in the RPE65 or LRAT gene or having an endogenous retinoid deficiency, as well as in a subject with retinitis pigmentosa.EFFECT: effective improvement of visual function without side effects.182 cl, 14 dwg, 7 tbl, 6 ex
ethod for treatment of macular edema of retina // 2635530
FIELD: medicine.SUBSTANCE: prolonged corticosteroid diprospan is administered to the subtenon space. After 10-15 days, laser coagulation of the retina is performed. After 15-20 days, intravitreal administration of ranibizumab is carried out.EFFECT: improved visual acuity, fast reduction of retinal edema and reduced risk of neovascular complications development.2 ex
Composition for auditory passage care and hygiene // 2635520
FIELD: pharmacology.SUBSTANCE: invention is a composition for auditory passage care and hygiene, comprising: a surfactant pair that consists of sodium lauryl sarcosinate and sucrose laurate, wherein the composition contains 3% to 6% by weight with respect to the sodium lauryl sarcosinate composition weight and 1% to 3% by weight with respect to the weight of sucrose laurate composition and auxiliary substances or additives.EFFECT: creation of a composition for auditory passage care and hygiene, in particular a cerumenolithic composition effective for dissolution and prevention of earwax plugs formation, that does not contain irritant products or allergy sources such as preservatives or animal surfactants, that is biodegradable and non-toxic to the environment, which does not require washing after application.8 cl, 1 tbl, 1 ex
ethod for optic nerve atrophy treatment after craniocerebral injury // 2635485
FIELD: medicine.SUBSTANCE: when treating optic nerve atrophy after a craniocerebral injury, 1000 mg of Recognan in 4 ml of 0.9% saline is injected intravenously once a day. In addition, from the first day of treatment, 10 sessions of endonasal electrophoresis are performed from the negative pole for 20 min with 10 mg of chymotrypsin, diluted in 5 ml of 0.2% saline. The course of treatment is 10 days.EFFECT: method provides stabilization of visual functions while reducing the pharmacological load on the body, long term effect, absence of complications associated with the central nervous system.2 ex
Preservative-free topical composition, including hyaluronic acid // 2635473
FIELD: pharmacology.SUBSTANCE: invention is a topical composition for stimulation of skin or mucous membranes scarring, containing less than 1 CFU/ml of aerobic flora and free of preservatives, which contains, based on the total weight of the composition: at least 0.1 wt % of hyaluronic acid, a mixture of low molecular weight hyaluronic acid having a molecular weight of 600 to 1,000 kDa, and a high molecular weight hyaluronic acid having a molecular weight of 800 to 1,200 kDa, the said high molecular weight hyaluronic acid has a higher molecular weight than the said low molecular weight hyaluronic acid; at least one agent for skin scarring and water. The invention provides a composition where the high molecular weight hyaluronic acid enhances scarring by its film-forming effect, while the low molecular weight hyaluronic acid, due to its penetrability, enhances composition components penetration into tissues.EFFECT: improved healing properties, improves the epidermis structure and accelerates the differentiation of the granulation tissue.7 cl, 2 ex, 2 tbl
ethod for purulent corneal ulcers treatment // 2635454
FIELD: medicine.SUBSTANCE: de-epithelialization and corneal cross-linking are conducted. When conducting cross-linking, instillations of a photosensitizer and a broad-spectrum antibiotic or antifungal agent are alternated. The purulent infiltrate zone is directly affected by ultraviolet radiation.EFFECT: increased antibacterial and antifungal effect of cross-linking in the ulcer area with an increased rate of resorption and purification of the ulcer from purulent content with a reduction in the number of complications, eliminating the need for emergency keratoplasty and improved conditions for possible subsequent keratoplasty.7 cl, 2 ex
Pharmaceutical preparation for prevention and treatment of progressive myopia // 2635185
FIELD: pharmacology.SUBSTANCE: pharmaceutical preparation for progressive myopia prevention and treatment contains an effective amount of primary or secondary amine with functional groups in the form of a salt or of a complex transition metal compound or a mixture thereof. During preparation of the said pharmaceutical preparation, neutralisation of the primary or secondary amine with functional groups with an acid is performed.EFFECT: increased effectiveness of progressive myopia prevention and treatment.33 cl, 5 tbl, 19 ex
ethod for complex treatment of endogenous uveitis followed by macular edema // 2635083
FIELD: medicine.SUBSTANCE: alternately, on the side of the affected eye, pterygopalatine and BTE drug injections are performed and ultraviolet irradiation of blood is performed. Pterygopalatine injections are performed by introducing platelet-enriched autoplasma at a dose of 3-5 ml by a course of 3-4 injections with an interval of 72-96 hours. BTE injections are performed by administering a drug mixture containing dalargin 1 mg, lidocaine 40 mg, mexidol 50 mg, gemaza 5000 ME. The course of treatment is 6-7 injections daily. In addition, an intravenous injection of ozonized saline with an ozone concentration of 400-800 mcg/l, volume of 150-200 ml, at a rate of 30-40 drops per minute, with a course of 6-7 injections, is performed daily.EFFECT: persistent long-term clinical outcome, consisting in improved visual functions, increased visual acuity due to relief of inflammation in the uveal tract.3 cl, 6 dwg, 3 ex
ethod for electrophoresis during therapy of distrophic processes of eyeball front division based on flow system of drug or mineral water reception // 2634607
FIELD: medicine.SUBSTANCE: drug solution or mineral water are electrophoretically injects into the eye tissue in the bath. The solution is continuously fed through a tube with a pressure of 0.5-0.6 atm into a bath, which is made in the form of a metal funnel with a depression at its narrow part transfer into a wide one for securing the electrode through which the electric current is led to the funnel. And the patient's head is held turned towards the funnel, so that the solution hits the open eye, constantly irrigating the anterior section, including the conjunctiva, cornea and eyelids, due to the solution natural outflow over the funnel edge.EFFECT: prevention of decomposition products re-absorption due to flowing effect, increase of electrophoretic saturation of eye tissues with drug or mineral water due to an increased galvanization area in absence of the need for bath close contact with the eye.2 dwg, 2 ex
Fused protein, inhibiting angiogenesis or growth of vessels, and its application // 2634406
FIELD: biotechnology.SUBSTANCE: fused protein consisting of the KH02, KH03 or KH04 fragments of the receptor of human vascular endothelial growth factor (VEGF) of the human and the human immunoglobulin Fc-fragment, bound together, is obtained.EFFECT: invention makes it possible to obtain a biologically active fused protein with high thermal stability, a significantly reduced rate of formation of protein aggregates during the fermentation process, and a substantial increase of the purity and yield of the protein.15 cl, 4 dwg, 11 tbl, 7 ex
ethod for selection of irrigation system for emergency help for patients after chemical and thermal eye burns of first or second degrees // 2634293
FIELD: medicine.SUBSTANCE: type of burn - chemical or thermal - is determined. The overall thickness of the cornea, the thickness of the cornea in the central optical zone, visual acuity is determined. The intensity of corneal epithelium damage zone staining with a vital dye is estimated. Endothelial cells density is determined according to computer keratotopography. The content of endothelial cells with pleomorphism and polymegatism is determined according to confocal microscopy. With a chemical burn with lesions of eyelids and conjunctiva, a decrease in vision to 0.6-0.8, corneal staining - II moderate intensity, a decrease in the cornea thickness in the central optical zone of not more than 25 mcm relative to the norm, reduced total cornea thickness of not more than 30 mcm relative to the norm, endothelial cells density of not more than 2500 cells/mm, polymegatism of not less than 40%, pleomorphism of not more than 35%, sterile solution of 0.9% sodium chloride is used as an irrigation system. With a chemical burn with corneal damage, a decrease in vision to 0.3, corneal staining - III medium intensity, a decrease in the cornea thickness in the central optical zone of not more than 30 mcm relative to the norm, reduced total cornea thickness of not more than 30 mcm relative to the norm, endothelial cells density of not more than 2400 cells/mm, polymegatism of 40-45%, pleomorphism of not more than 40%, a neutral 4.9% buffer solution of phosphate salts is used as an irrigation system. With a thermal burn with eyelids and conjunctiva lesions, a decrease in vision to 0.6-0.8, corneal staining - I low intensity, an increase in the cornea thickness in the central optical zone of not more than 25 mcm relative to the norm, increased the total cornea thickness of not more than 10 mcm relative to the norm, endothelial cells density of no more than 2700 cells/mm, polymegatism of not less than 30%, pleomorphism of more than 50%, sterile 0.9% sodium chloride solution is used as an irrigation system. With a thermal burn with corneal damage, a decrease in vision to 0.6-0.8, corneal staining - II moderate intensity, an increase in the cornea thickness in the central optical zone of not more than 50 mcm relative to the norm, increased total cornea thickness of not more than 20 mcm relative to the norm, endothelial cells density of not more than 2500 cells/mm, polymegatism of not less than 35%, pleomorphism of not more than 40%, neutral 4.9% buffer solution of phosphate salts is used as an irrigation system.EFFECT: high functional result in the outcome of thermal and chemical burns of the first or second degree, accurate timely diagnosis of the state of the cornea and timely application of optimal clinical conditions of irrigation solutions for emergency care by evaluating the complex of the most significant indicators.4 ex
Aqueous ophthalmic solution based on cyclosporin a // 2634267
FIELD: pharmacology.SUBSTANCE: stable aqueous ophthalmic solution contains an immunosuppressive agent, a cellulose derivative as the first polymer, a polyvinyl derivative as the second polymer, and a lipophilic functional polymer as the third polymer. This solution does not contain an organic solvent, an antimicrobial preservative and does not actually contain particles. To produce the said solution, an immunosuppressant is solubilized in the presence of at least a portion of the first polymer, in the presence of water; any remaining part of the first polymer is mixed with two other polymers, water and optionally buffer systems and isotonic agents; and the products obtained in the previous steps are mixed. For treatment of disorders associated with the eye surface, having an inflammatory-immune base, the said solution is administered to humans or animals.EFFECT: effective treatment of ophthalmic diseases of inflammatory-immune genesis.17 cl, 3 dwg, 3 tbl, 6 ex
ethod for determination of differentiated indications to terms of precorneal lacrimal film damages treatment after laser in situ keratomileusis with femtolaser support in children // 2633349
FIELD: medicine.SUBSTANCE: after surgery, osmolarity of the lacrimal fluid and the superficial corneal layers epithelium are examined by confocal microscopy of the cornea. When the osmolarity of the fluid rises above 340 mOsm/l within 6 months after surgery, and a severe degree of degenerative changes in the epithelium and the anterior stroma of the cornea are observed, the treatment is carried out for 3 months: corneoprotectors instillations 4 times a day for 1 month, then only overnight, and tear-replacing drugs instillations without preservatives 6 times a day for 1 month, then 4 times a day. In the presence of osmolarity in the range from 320 to 340 mOsm/l and a moderate degree of degenerative changes in the epithelium and anterior stroma of the cornea for 2 months, the treatment is carried out: corneoprotectors instillations 4 times a day for 1 month, then only overnight, and tear-replacing drugs instillations without preservatives 4 times a day. In the presence of osmolarity of up to 320 mOsm/l and insignificant degree of degenerative changes in the epithelium and anterior stroma of the cornea, corneoprotectors and tear-replacing drugs instillations are performed 4 times a day for 1 month.EFFECT: reduced risk of xerotic and trophic corneal changes development.3 ex
ethod for surgical treatment of endophtalmitis // 2633340
FIELD: medicine.SUBSTANCE: method comprises performing a vitrectomy with a temporary endotamponade by a perfluoroorganic compound (PFOC). Treatment begins within the first 12 hours from the first symptoms of the disease. In the process of tamponade of the vitreal cavity, 1 mg of vancomycin in 0.1 ml of 0.9% sodium chloride solution is added to PFOC, followed by replacement with BSS+ solution or silicone oil 7-14-day after. During the tamponade of the vitreous cavity of PFOC, antibacterial drugs which suppress the growth of the identified etiologic agent are additionally intravitreally administered.EFFECT: method provides relief of the inflammatory reaction in the anterior and posterior segments of the eye and the maximum possible preservation of visual functions.2 ex
Ophthalmological means for corneal injuries and diseases diagnostics // 2633083
FIELD: medicine.SUBSTANCE: means contains: riboflavin mononucleotide 1.0 wt %, hydroxypropylmethylcellulose 1.0 wt % and physiological solution on a phosphate buffered basis - the rest.EFFECT: use of the invention ensures formation of a stable pre-corneal colour film of prolonged action due to the viscosity properties of the solution and the natural diffusion of riboflavin into the corneal stroma through defective epithelium sites, providing additional therapeutic activity of the active and auxiliary substances.3 ex
Ophthalmic composition for treatment of conjunctivites, bleparitis and marginal corneal ulcers in topical application // 2633055
FIELD: pharmacology.SUBSTANCE: invention is an ophthalmic composition containing an active substance, excipients and a consistent-forming base, characterised by containing (11beta,16alpha)-16,17-(butylidenbis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione(budesonide) and hyaluronic acid or sodium hyaluronate as an active substance, and boric acid as an auxiliary substance, the components in the composition being in a certain ratio %.EFFECT: increased therapeutic effectiveness of the claimed composition due to the combined action of budesonide and a hyaluronic acid source with prolonged drugs action and increased contact time of the composition with the eye cornea, reduced therapy course, excluded relapses of diseases and complications, and also a low degree of absorption with more pronounced action, simplicity in performance and good tolerability of patients suffering from eye inflammatory diseases of non-infectious etiology and allergic lesions of the ocular surface.2 cl, 4 ex
Gel pharmaceutical composition for blepharitis treatment // 2633054
FIELD: pharmacology.SUBSTANCE: invention is a pharmaceutical composition comprising recombinant interferon, metronidazole, fluconazole, boric acid and a consistently forming base, characterized by further comprising hyaluronic acid or sodium hyaluronate, the components in the composition being in a certain ratio %.EFFECT: increased therapeutic effect by expanding the drug spectrum, including complex anti-inflammatory, antifungal, antibacterial, antiviral, acaricidal and anti-allergic action, as well as due to the prolonged treatment effect of the drug.2 cl, 10 ex
Antimicrobial tympanic shunt // 2632766
FIELD: medicine.SUBSTANCE: invention relates to the treatment of diseases of a middle ear and an eustachean tube. For this purpose, a tympanic shunt is proposed, consisting of a vent pipe with two flanges at opposite ends and a slot valve on one of the flanges, made of a silicone composition containing rifampicine in an amount of 1-3 wt %.EFFECT: prolonged antibacterial action with stable physico-mechanical properties of the shunt necessary for its installation to the patient.2 cl, 1 ex, 2 tbl
Photosensibilizers based on (bacterio)chlorophyll for treatment of eye diseases and disorders // 2632439
FIELD: pharmacology.SUBSTANCE: invention provides application of bacteriochlorophyll compounds for preparation of a pharmaceutical composition for photodynamic therapy of diseases, disorders and conditions associated with corneal and scleral anomalies selected from cornea thinning and sclera weakening. The invention also includes methods of photodynamic therapy for cornea thinning or sclera stretching, comprising the steps of administration of a pharmaceutical composition containing a bacteriochlorophyll compound to a subject suffering from cornea thinning or sclera stretching; and eye irradiation with light at a wavelength in the red or near infrared region of the spectrum.EFFECT: invention allows preparation of alternative photosensibilizer that can provide collagen cross-linking in the vast posterior sclera regions with maximum safety in relation to the retina and orbital tissues.16 cl, 18 dwg, 2 tbl, 16 ex
Oral pharmaceutical composition for prevention or treatment of "dry eye" syndrome containing rebamipid or its precursor // 2632107
FIELD: pharmacology.SUBSTANCE: oral pharmaceutical composition for "dry eye" syndrome prevention or treatment, comprising a renamipide precursor or a pharmaceutically acceptable salt thereof in an amount of 0.5 to 1 wt % as an active ingredient. The composition is in the form of a suspension. Also an oral pharmaceutical preparation, a method for "dry eye" syndrome prevention or treatment and application of a renimidine precursor for pharmaceutical drug preparation are described. These rebamipide precursors can treat the "dry eye" syndrome with oral route of administration.EFFECT: safety and ease of use compared with conventional eye drops.10 cl, 15 dwg, 1 tbl, 28 ex
Hyposmotic ophthalmic means for ultraviolet crosslinking of thin corneas // 2631604
FIELD: medicine.SUBSTANCE: hypoosmotic ophthalmic means contains riboflavin mononucleotide, hydroxypropylmethylcellulose, tris-(hydroxymethyl)-methylamine, nipagin and purified water. The ingredients are used in the declared ratio.EFFECT: use of the invention provides stroma hydration, necessary increase in the cornea thickness by means of the hypoosmotic properties of the solution, optimal intrastromal concentration of riboflavin, reduced instillations due to stable precorneal film formed by hydroxypropylmethylcellulose introduction.1 ex

Drugs and methods for treatment of presbyopia, moderate hypermetropy and incorrect asygmaticism // 2630968
FIELD: medicine.SUBSTANCE: for the treatment of presbyopia, a therapeutically effective amount of a composition comprising pilocarpine and oxymetazoline is administered to the subject's eye.EFFECT: use of the invention improves presbyopia treatment through synergistic action of pilocarpine and oxymetazoline while minimizing the side effects of each compound.9 cl, 3 tbl, 7 dwg, 8 ex
Nitrogen-containing spirocyclic compound and its application in medicine // 2630694
FIELD: pharmacology.SUBSTANCE: compounds can be used to prepare a medicament for treatment or prevention of a disease selected from the group consisting of organ transplant rejection, graft versus host transplantation, autoimmune disease, allergic diseases and chronic myeloproliferative disease. The disease can be selected from rheumatoid arthritis, psoriasis, atopic dermatitis or a disease caused by dry eyes. In the general formula Ra is the same or different and each represents (1) C1-6 alkyl or (2) a halogen atom, n1 is an integer selected from the integers from 0 to 2, Rb are the same or different and each represents (1) C1-6 alkyl or (2) halogen atom, n2 is an integer selected from the integers from 0 to 2, m1 is an integer selected from the integers from 0 to 3, m2 is an integer selected from the integers from 1 to 4, Xa=Xb is (1) CH=CH, (2) N=CH or (3) CH=N, X is (1) a nitrogen atom or (2) C-Rd, where Rd is a hydrogen atom or halogen atom, Rc is a group selected from the following groups (1)-(6): (1) a hydrogen atom, (2) C1-6 alkyl, optionally substituted with 1-5 same or different substituents selected from the following group A, (3) -C(=O)-Rc1, (4) -C(=O)-O-Rc2, (5) -C(=O)-NRc3Rc4, where Rc1, Rc2, Rc3, Rc4 are the same or different and each represents (i) a hydrogen atom or (ii) C1-6 alkyl, optionally substituted with 1-5 same or different substituents selected from the following group A, or (6) a group of the following formula in which Ya is a group selected from the following groups (i) to(iii) (i) C1-6 alkylene, (ii) -C(=O)- or (iii) -S(=O)-O-, ring T is (i) a phenyl, (ii) C3-10 cycloalkyl or (iii) a saturated monoheterocyclyl, which contains 1 nitrogen atom and carbon atoms, and the number of atoms, constituting the ring, is 3-7, Rc5 is the same or different and each represents (i) cyano, or (ii) a nitro group, p is an integer selected from the integers from 0 to 1, group A is a group, consisting of (a) a hydroxyl, (b) C1-6 alkoxy, (c) a cyano, (d) C1-6 alkoxycarbonyl, (e) C1-6 alkylcarboxylic and (f) C2-6 alkenylacyl.EFFECT: increased efficiency of treatment.60 cl, 33 tbl, 8 ex

Pharmaceutical composition // 2630617
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for treatment of cyclooxygenase-2 mediated diseases is described. The said composition includes, (2S)-7-tret-butyl-6-chloro-2- (trifluoromethyl)-2H-chromene-3-carboxylic acid as the active substance and a filler selected from tromethamine or meglumine. The filler is used in an amount of 0.5 wt % to 70 wt %. Two versions of the method for preparation of this composition and its application are also described.EFFECT: increased dissolution rate and oral bioavailability of the said composition, including the free form of the said compound.9 cl, 5 dwg, 16 tbl, 6 ex
Ophthalmatic compositions containing substituted gamma-lactames and methods of their application // 2630594
FIELD: pharmacology.SUBSTANCE: ophthalmic composition for ocular hypertension treatment comprises at least one therapeutically active agent in a concentration of 0.01 to 0.12% (w/v), at least one tonicity agent, glycerin or mannitol, a solubilizer-polysorbate 80 and a preservative- benzalkonium chloride. The therapeutically active agent has the structure where X1 and X2 independently represent CH2, O or S, and R1 is H or C1-C6 alkyl.EFFECT: application of a group of inventions allows to increase the efficiency of ocular hypertension treatment due to a novel combination of ingredients of the composition where the active agent solubility is increased.19 cl, 8 tbl, 10 ex

Protective agent for cornea and conjunctiva or suppressive agent in case of keratoconjunctivitis // 2630581
FIELD: pharmacology.SUBSTANCE: group of inventions is a protective agent for cornea and conjunctiva, as well as a suppressant in case of keratoconjunctival disorder, comprising glycosylglycerin as an active ingredient, wherein the glycosylglycerin comprises at least one glycosylglycerin selected from the group consisting of 1-glyceryl glycosideα,αββ 2-glyceryl glycoside, 1-glyceryl glycoside and 2-glyceryl glycoside, and where the agent is used to protect the conjunctiva and cornea in case of Sjogren's syndrome, Stevens-Johnson syndrome, dry eye syndrome, exogenous disease caused by a postoperative condition, drug, damage or contact lens wear; and application of the said glycosylglycerin for preparation of a drug for conjunctiva and cornea protection and keratoconjunctival disorder suppression; as well as a method for cornea and conjunctiva protection and keratoconjunctival disorder suppression, comprising administration of the said glycosylglycerin.EFFECT: invention provides allergic symptoms relief.6 cl, 3 ex, 1 tbl, 1 dwg
ethod for determining level of endolymphatic hydrops in meniere disease, selection of treatment strategy and evaluation of its efficiency // 2630129
FIELD: medicine.SUBSTANCE: group of inventions consists of a method for determining the level of endolymphatic hydrops (EHL), a method for selecting the EHL treatment strategy, and a method for evaluating the EHL treatment efficacy in Meniere disease. The patient is intratympanically injected with 1 ml of eightfold diluted contrast agent (CA). 24 hours after MRI with a magnetic field strength of 3 Tesla and 8-channel coil is carried out. The obtained data are used to assess the accumulation of CA and its value in the vestibule and semicircular canals. In the absence of CA accumulation in the vestibule and semicircular canals, a significant vestibular and canal hydrops is determined. If the CA accumulation is less than 50% of the area of the vestibule and if the CA is absent in the semicircular canals, a moderate vestibular and significant canal hydrops are determined. If the CA accumulation is more than 50%, but less than 70% of the area of the vestibule and the CA is present at less than 50% of the area of the semicircular canals, a small vestibular and moderate canal hydrops are determined. If the CA accumulation in the semicircular canals and in vestibule is more than 50%, but less than 70% of the area, an insignificant canal and insignificant vestibular hydrops are determined. If the CA accumulation in the vestibule and semicircular canals is more than 70% of the area, the absence of the hydrops is determined. The EHL treatment strategy is determined taking into account the revealed level. If a significant vestibular and canal hydrops are detected, dehydration therapy is carried out. If a moderate vestibular and significant canal hydrops are detected, dehydration therapy is carried out. If an insignificant vestibular and moderate canal hydrops are detected, dehydration therapy or intratympanic gentamycin treatment is carried out. If an insignificant vestibular and insignificant canal hydrops are detected, an intratympanic gentamycin treatment is carried out. To evaluate the EHL treatment efficacy in Meniere disease, the second MRI is performed to assess the CA accumulation and its value in the vestibule and semicircular canals. If the CA accumulation area is increased, the conducted treatment is considered to be effective.EFFECT: accurate and objective assessment.4 cl, 1 ex
Gel eye drops for chronic and allergic inflammatory diseases treatment // 2629590
FIELD: medicine.SUBSTANCE: gel eye drops include dexamethasone sodium phosphate, a hyaluronic acid source, histidine hydrochloride monohydrate, boric acid, sodium tetraborate, polyethylene glycol, disodium edetate, potassium chloride, sodium chloride and water. The ingredients are used in the declared amounts.EFFECT: use of the invention allows to effectively treat chronic and allergic inflammatory eye diseases of different severity without side effects and allergies.10 ex
Esters for ophthalmological inflammatory diseases treatment // 2627438
FIELD: pharmacology.SUBSTANCE: this invention relates to a composition comprising an esterified anti-inflammatory lipoid mediator which is an anti-inflammatory lipid mediator ether that is the product of the reaction of an anti-inflammatory lipid mediator and a monohydric alcohol or amide, with most of the anti-inflammatory lipoid mediator present in the form of an ester. Thus, the compositions contain 10 wt % or less of the acid form of the anti-inflammatory lipoid mediator. Anti-inflammatory lipid mediators may be selected from the group consisting of polyunsaturated fatty acids (for example, omega-3 and omega-6 fatty acids), resolvins or a metabolically stable analogue, proteins or metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analogue, retinoic acid, endocannabinoids, their metabolites and mixtures.EFFECT: composition can be delivered locally to the eye surface with an impregnated or hydrated contact lens.30 cl
Aryl urea derivatives as n-formilepeptide-1 receptor (fprl-1) modulators // 2627271
FIELD: pharmacology.SUBSTANCE: invention relates to a compound represented by formula , or pharmaceutically acceptable salts thereof, wherein R6 is -CH2-(C6-10)aryl or -CH2-heterocycle, wherein the heterocycle is pyridine or indole; R7 is H, F or methyl; R8 is Br or F; R9 is H, F or methyl; R10 is OH or NH2; and including specific structures or pharmaceutically acceptable salts thereof. The invention also relates to a compound represented by formula , or pharmaceutically acceptable salts thereof, wherein R11 is C1-C6 alkyl; R12 is H; R13 is Br; R14 is H; R15 is OH or NH2; R16 is C1-C6 alkyl. and EFFECT: aryl urea derivatives as N-formylpeptide receptor-1 modulators.14 cl, 6 tbl, 6 ex
ethod for prevention of oculomotor muscles postoperative adhesions // 2627114
FIELD: medicine.SUBSTANCE: to implement the invention, a viscoelastic solution with a hyaluronic acid content of 2.5%, molecular weight of 3⋅106 D and a zero shear viscosity of 103 PaS is injected⋅ subconjunctivally. This solution is administered immediately after muscle fixation to the sclera before conjunctiva suturing under visual control. The solution is administered under the operated oculomotor muscle in a volume that provides its envelopment. Then, after conjunctiva suturing, the solution is injected into the subconjunctival space in a volume that provides conjunctiva separation from the sclera and muscle.EFFECT: pronounced antiscar effect after operations in the region of oculomotor muscles.3 cl, 1 ex
Water-based liquid composition with bromfenac possessing preservative effectiveness // 2625755
FIELD: chemistry.SUBSTANCE: invention represents the use of bromfenac or its salt to improve the preservative effectiveness of the water-based liquid composition, comprising (a) bromfenac or its salt and (b) benzalkonium chloride, and c) at least one agent selected from the group consisting of nonionic surfactant and water-soluble polymer. The invention also relates to a method of improving the preservative effectiveness of the aqueous solution described above, which comprises adding of bromfenac or its salt in an amount of 0.1 w/v % to the solution.EFFECT: invention enables to obtain a composition with imroved preservative activity, wherein there are low concentrations of benzalkonium chloride preserving agent.10 cl, 21 tbl, 4 ex

Ophthalmic composition // 2625301
FIELD: pharmacology.SUBSTANCE: ophthalmic composition contains a formula compound, where the values for R1 and R2 groups are given in the claims, and an ophthalmologically acceptable carrier. The invention also relates to a method for dry eye treatment, comprising local administration of a therapeutically effective amount of the ophthalmic composition to the eye of the subject in need.EFFECT: increased efficiency.20 cl, 6 dwg, 6 ex
Bimatoprost and thymolol solutions not containing conservants // 2624534
FIELD: pharmacology.SUBSTANCE: invention relates to a composition of bimatoprost and timolol containing no preservatives to reduce intraocular pressure in a human, containing the following composition: 0.03% w/o bimatoprosta; 0.5% w/o timolol; 0.268% w/o sodium phosphate dibasic heptahydrate; 0.014% w/o citric acid monohydrate; 0.68% w/o sodium chloride and water, and having a pH of 7.3. The invention provides a formulation that does not contain any antimicrobial preservative that is stable in solution for a long time at ambient temperature and is also stable in the plastic packaging in which it is usually stored.EFFECT: compositions of the invention are more effective in treating increased IOP than compositions with preservatives, and have a lower risk of side effects.8 cl, 1 tbl
ethod for complex treatment of infectious acute optical neuritis // 2623870
FIELD: medicine.SUBSTANCE: to treat infectious acute optical neuritis, retrobulbar infusions of dexamethasone and emoxipin are performed for 10 days via an irrigation system. Simultaneously, three immunomodulating preparations are used: 6 mg of polyoxidonium dissolved in 200.0 ml of physiological solution are injected intravenously every day; endonasal electrophoresis with 0.25% derinat solution at a current strength of 0.5-1 mA for 8 to 10 minutes; 2 ml of 12.5% of cycloferon are injected intramuscularly according to the scheme: the first 2 days - daily, the next 3 injections - every other day and the remaining 5 injections - every 3 days.EFFECT: use of the invention allows to restore the antibacterial and antiviral functions of the immune system, normalize the mechanisms of antioxidant protection, neuro-trophic activity, prevent the negative effects of GCS therapy, shorten the periods of inflammatory reaction arrest in the optic nerve and restore visual functions.2 ex
 
2550937.
Up!